Sopharma AD reports sale of treasury shares totaling BGN 108,248

Ognian Ivanov Donev
Ognian Ivanov Donev
0Comments

Sopharma AD has announced the sale of 43,600 treasury shares on August 27, 2025. The transaction represents 0.01% of the company’s share capital and was conducted at a total value of BGN 108,248.00 on the Bulgarian Stock Exchange. The average price per share in this sale was BGN 2.48.

Following this transaction, Sopharma AD now holds a total of 20,451,941 treasury shares, which accounts for 3.79% of its share capital.

“Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 27, 2025 the Company sold 43 600 (forty-three thousand and six hundred) treasury shares representing 0.01% of the share capital of the Company, at a total value of BGN 108 248.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.48.”

The company made this disclosure in accordance with Article 17 of Regulation (EU) No 596/2014 by the European Parliament and Council.

The current number of treasury shares held by Sopharma AD after this transaction stands at over twenty million.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.